Immunocytochemical localization of cathepsin D and CA 125 in ovarian cancer

International Journal of Gynecology and Obstetrics

Volumn 56, Issue 1, 1997, Pages 31-37

  Athanassiadou, P ^a   Sakellariou, V ^b   Michalas, S ^b   Petrakakou, E ^a   Athanassiades, P ^b   Aravantinos, D ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ALEXANDRA HOSPITAL   (Greece)

Author keywords

CA 125; Carcinoma; Cathepsin D; Immunocytochemistry; Ovarian; Prognostic factors

Indexed keywords

AVIDIN; BIOTIN; CA 125 ANTIGEN; CATHEPSIN D; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; CLINICAL TRIAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; MICROSCOPY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; STATISTICAL ANALYSIS; TUMOR VOLUME;

EID: 0031028746     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7292(96)02792-0     Document Type: Article

References (23)

1. [1] van Kamp GJ, Verstraeten AA, Kenemans P. Discordant serum CA 125 values in commercial immunoassays. Eur J Obstet Gynecol Reprod 1993; 49: 99-103.
2. [2] Gallion H, Bast R. National Cancer Institute conference on investigational strategies for detection and intervention in early ovarian cancer. Cancer Res 1993; 53: 3839-3842.
3. [3] Cannistra S. Cancer of the ovary. New Engl J Med 1993; 18: 1550-1559.
4. [4] Di-Xia C, Schwartz P, Qin L. Saliva and serum CA 125 assays for detecting malignant ovarian tumors. Obstet Gynecol 1990; 75: 701-704.
5. [5] Jacobs J, Bast RC. The CA 125 tumor associated antigen: a review of the literature. Hum Reprod 1989; 4: 1-12.
6. [6] Helzlsouer KJ, Bush TL, Albert AJ, Bass KM, Zacur H, Comstock GN. Prospective study of serum CA 125 levels as markers of ovarian cancer. J Am Med Assoc 1993; 269: 1123-1126.
7. [7] Rose PG, Reale FR, Longcope C, Hunter PE. Prognostic significance of estrogen receptor and progesterone receptor in epithelial ovarian cancer. Obstet Gynecol 1990; 76: 258-263.
8. [8] Harding M, Cowan S, Hole D, Cassidy L, Kitchener H, Davis J, Leake R. Estrogen and progesterone receptors in ovarian cancer. Cancer 1990; 65: 486-491.
9. [9] Scambia G, Panici PB, Ferrandina G, Salerno G, D'Agostino G, Distefano M et al. Clinical significance of Cathepsin D in primary ovarian cancer. Eur J Cancer 1994; 30A: 935-940.
10. [10] Winstanley J, Leinster S, Cooke T, Westley B, Platt-Higgins A, Rudland P. Prognostic significance of Cathepsin D in patients with breast cancer. Br J Cancer 1993; 67: 767-772.
11. [11] EORTC Breast Cancer Cooperative Group. Revision of the standards for the assessment of hormone receptors in woman breast cancer. Eur J Cancer 1980; 16: 1513-1515.
12. [12] Brouillet J, Theillet C, Maudelonde T, Defranne A, Simony-Kafontaine J, Sertour J et al. Cathepsin-D assay in primary breast cancer and lymph nodes; relationship with c-myc, c-erb-B-2 and int-2, oncogene amplification and mode invasiveness. Eur J Cancer 1991; 26: 437-441.
13. [13] Briozzo P, Morisset M, Capony F, Rougeot C, Rochefort H. In vitro degradation of extracellular matrix with Mr 52000 cathepsin D secreted by breast cancer cells. Cancer Res 1988; 48: 3688-3692.
14. [14] Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577-580.
15. [15] Kumar V, Cotran R, Robbins S. Basic Pathology. W.B. Saunders Co. 1992: 621-628.
16. [16] Morisset M, Capony F. The 52 kDa estrogen induced protein secreted by MCF-7 cells is a lysosomal acidic protease. Biochem Biophys Res Commun 1986; 138: 102-106.
17. [17] Westley B, May F. Oestrogen regulates Cathepsin D mRNA levels in oestrogen-responsive human breast cancer cell lines. Nucl Acids Res 1987; 9: 3773-3786.
18. [18] Hengen-Logmans S, Fieret E, Berns E, van der Burg M, Klign J, Foekens J. Ki 67 staining in benign borderline, malignant primary and metastatic ovarian correlation with steroid receptors, epidermal-growth-factor receptor and Cathepsin D. Int J Cancer 1994; 57: 468-472.
19. [19] Isola J, Weitz S, Visakorpi T. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. J Clin Oncol 1993; 11: 36-43.
20. [20] Scambia G, Benedetti P, Ferrandina G, Battaglia F, Baiocchi G, Mancuso S. Cathepsin D assay in ovarian cancer: correlation with pathological features and receptors for oestrogen, progesterone and epidermal growth factor. Br J Cancer 1991; 64: 182-184.
21. [21] Leto G, Gebbia N, Rausa L, Tumminello FM. Cathepsin D in the malignant progression of neoplastic diseases (Review). Anticancer Res 1992; 12: 235-240.
22. [22] Tandon A, Clark G, Chamness G, Chirgwin J, McGuire W. Cathepsin D and prognosis in breast cancer. N Engl J Med 1990; 322: 297-302.
23. [23] Pagano M, Capony F, Rochefort H. In vitro activation of pro-Cathepsin B by Cathepsin D both secreted by cancer cells. CR Acad Sci Paris Serie III 1990; 309: 8-12.